Rx30/ComputerRx’s new Enhanced Medication Services (EMS) center is gaining significant traction with funded programs for its 8,600 pharmacies. Staffed and operated by pharmacists and technicians, EMS was formed to provide for maximum patient engagement and significant “quality lift” in driving higher pharmacy ratings on performance measures, reducing direct and indirect remuneration (DIR) impacts, and implementing a variety of programs and services that EMS will manage with and on behalf of Rx30/ComputerRx pharmacies.

Steve Wubker, president and CEO of Rx30/ComputerRx/EMS, describes the EMS model this way: “It’s great to have clinical service programs built into your pharmacy software, but until the financial model changes to meaningfully compensate pharmacists for taking on the multiple tasks required to effectively manage such programs as MTM, adherence, and med sync programs, pharmacists need a more realistic answer to where’s the real money? For an overwhelming majority the work is not getting done. We believe our EMS center is the answer.”

Wubker goes on to explain, “EMS can serve as the backstop to get these tasks accomplished in coordination with or on behalf of our Rx30/ComputerRx pharmacies, driving higher performance, healthier outcomes, and revenue. The absolute key is our size, power, and representation on their behalf. The model simply makes sense. With pharmacies now being penalized or rewarded based on performance, pharmacies need a strong advocate with the strength in numbers to have a voice and make a difference on their behalf. That’s EMS.”

Wubker says that Beth Bell has joined the EMS leadership team to head up business development. She brings a strong business development background in the healthcare industry to the company, previously working with innovators and leaders, including Inmar and Pleio. Bell will focus her efforts on strategic partnerships to extend the EMS brand.

The company has also announced that it has teamed up with Alpha Genomix to build genetic testing intelligence directly into the Rx30/ComputerRx pharmacy system platforms. In describing the benefit, Wubker says that it is his company’s belief that targeted medication therapy is going to be an important component in the future of prescription dispensing: “Our goal is to be the industry leader in streamlining the capabilities of identifying qualified patients, integrating drug/gene interactions, and providing the necessary tools and training to explain a patient’s genetic makeup and implications.”

Wubker reports that the company has also partnered with iMedicare to provide point-of-dispensing actionable intelligence regarding potential DIR impacts, drug depletion supplement recommendations, real-time Medicare eligibility notifications, and sign-on to the iMedicare Medicare plan comparison program. He says that this offering has been well received: “It’s simple, yet drives revenue and cost savings by providing actionable intelligence as you fill. It’s a great product at the right time.”